Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged cardiovascular
Will Amarin’s new cardiovascular patent lawsuit against Hikma keep out generic sales?

The battle continues. We previously wrote about the Federal Circuit’s decision in the case (GlaxoSmithKline v. Teva) and how that case may offer Amarin another chance to bar generics from the market for Vascepa®. Sure enough, on November 30, Amarin filed suit against Hikma asserting three patents covering use of EPA to treat cardiovascular events. What are the takeaways from this suit?

Read More
Markman AdvisorsAmarin, Amarin Pharmaceuticals, $AMRN, AMRN, Federal Circuit, GlaxoKlineSmith, Teva, Hikma, Dr. Reddy's, cardiovascular, Vascepa, hypertriglyceridemia, ANDA, Hatch-Waxman, REDUCE-IT, JELIS, Judge Du, Zachary Silbersher, Silbersher Comments
How will REDUCE-IT impact generic entry for Amarin’s Vascepa?

We previously blogged about the upcoming litigation trial between Amarin Pharmaceuticals ($AMRN) and Dr. Reddy’s and Hikma, which are two prospective generics for Amarin’s Vascepa®.  While that blog post provided a general overview of the issues to be litigated at the upcoming trial, there are numerous other issues and questions around the upcoming trial.  This post will focus on how the REDUCE-IT trial may impact Amarin’s fight with the existing generics, if at all.

Read More
Markman AdvisorsAmarin, Amarin Pharmaceuticals, AMRN, $AMRN, Dr. Reddy's, Hikma, Vascepa, EPA, generic, patent, off-label, off label, ANDA, Orange Book, FDA, DHA, LDL-C, Apo-B, hypertriglyceridemia, cardiovascular, Zachary Silbersher, Silbersher Comments